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Reactivation of latent HIV-1 provirus 
via targeting protein phosphatase-1
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Andrey V Ilatovskiy6,7, Yasemin Saygideğer Kont8, Andrey Ivanov3, Aykut Üren8, Dmytro Kovalskyy9, 
Michael Petukhov6,7, Fatah Kashanchi2 and Sergei Nekhai3,4*
Abstract 
Background: HIV-1 escapes antiretroviral drugs by integrating into the host DNA and forming a latent transcription-
ally silent HIV-1 provirus. This provirus presents the major hurdle in HIV-1 eradication and cure. Transcriptional activa-
tion, which is prerequisite for reactivation and the eradication of latent proviruses, is impaired in latently infected T 
cells due to the lack of host transcription factors, primarily NF-κB and P-TEFb (CDK9/cyclin T1). We and others previ-
ously showed that protein phosphatase-1 (PP1) regulates HIV-1 transcription by modulating CDK9 phosphorylation. 
Recently we have developed a panel of small molecular compounds targeting a non-catalytic site of PP1.
Results: Here we generated a new class of sulfonamide-containing compounds that activated HIV-1 in acute and 
latently infected cells. Among the tested molecules, a small molecule activator of PP1 (SMAPP1) induced both HIV-1 
replication and reactivation of latent HIV-1 in chronically infected cultured and primary cells. In vitro, SMAPP1 inter-
acted with PP1 and increased PP1 activity toward a recombinant substrate. Treatment with SMAPP1 increased phos-
phorylation of CDK9’s Ser90 and Thr186 residues, but not Ser175. Proteomic analysis showed upregulation of P-TEFb 
and PP1 related proteins, including PP1 regulatory subunit Sds22 in SMAPP1-treated T cells. Docking analysis identi-
fied a PP1 binding site for SMAPP1 located within the C-terminal binding pocket of PP1.
Conclusion: We identified a novel class of PP1-targeting compounds that reactivate latent HIV-1 provirus by tar-
geting PP1, increasing CDK9 phosphorylation and enhancing HIV transcription. This compound represents a novel 
candidate for anti-HIV-1 therapeutics aiming at eradication of latent HIV-1 reservoirs.
© 2015 Tyagi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite efficient antiretroviral therapy, eradication of 
human immunodeficiency virus (HIV) 1 infection is chal-
lenging and requires novel biological insights and thera-
peutic strategies. Eradication of latent HIV-1 provirus is 
especially challenging as integrated HIV-1 is not affected 
by the existing anti-HIV-1 drugs unless viral transcrip-
tion is activated [1]. Efficient HIV-1 transcription from 
HIV-1 long terminal repeat (LTR) requires both host 
cell factors and HIV-1 Tat protein [2]. HIV-1 Tat protein 
recruits the positive transcription elongation factor b 
(P-TEFb), a heterodimeric complex consisting mainly of 
cell cycle-dependent kinase (CDK) 9 and cyclin T1, to 
the transactivation response (TAR) RNA [3]. Separately, 
Tat also recruits histone acetyl transferases (HATs) [4–6] 
and SWI/SNF remodeling complex [7] to induce tran-
scription from the integrated HIV-1 promoter. P-TEFb 
activity is repressed by the chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) interacting 
protein 2 (STIP2) which also represses HIV-1 promoter 
and blocks HIV-1 transcription in microglia [8]. STIP2-
repressed P-TEFb is recruited to HIV-1 and cellular pro-
moters by high mobility group AT-hook 1 (HMGA1) 
protein [9]. P-TEFb triggers HIV-1 transcriptional elon-
gation via the phosphorylation of the C-terminal domain 
(CTD) of RNA polymerase II (RNAPII), the nega-
tive elongation factor (NELF) and the DRB-sensitivity 
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inducing complex (DSIF/Spt4/Spt5) [1, 10]. P-TEFb in 
the cells exists in the form of distinct molecular weight 
complexes [11]. A low molecular weight, functionally 
active kinase consists of CDK9 and cyclin T1 subunits 
[10]. However, the enzymatically inactive, high molecular 
weight complex carries other additional factors, includ-
ing 7SK RNA, HEXIM1 protein, La-related LARP7 pro-
tein [12–14] and the methylphosphatase capping enzyme 
MePCE [15, 16]. The high molecular weight complex 
serves as a source of P-TEFb, from which HIV-1 Tat 
extracts P-TEFb and recruits it to HIV-1 LTR [17]. Sub-
sequently, Tat facilitates the formation of super-elonga-
tion complex (SEC) at HIV-1 LTR, which, in addition to 
P-TEFb, also carries additional elongation factors and 
co-activators [18, 19]. Enzymatic activity of P-TEFb and 
its interaction with Tat is regulated by phosphorylation 
of CDK serine/threonine residues located in the regula-
tory T-loop [11]. Phosphorylation of CDK9 at Thr186 is 
required for its enzymatic activity [20, 21]. We and others 
have previously shown that protein phosphatase-1 (PP1) 
dephosphorylates CDK9’s Thr 186 [22, 23]. Moreover, we 
also showed that PP1 dephosphorylates CDK9’s Ser 175 
[22]. A recent study by Jonathan Karn and colleagues 
showed that phosphorylation of CDK9 Ser175 occurs 
during the induction of latent HIV-1 provirus and that 
Tat Lys12 forms a hydrogen bond with CDK9’s phospho-
Ser175 [24]. Thus, interaction between Lys12 of Tat and 
phosphorylated CDK9’s Ser175 facilitates the binding 
of Tat to P-TEFb [24]. We have recently demonstrated 
that phosphorylation of CDK9 at Ser90 by CDK2 alters 
CDK9 association with 7SK snRNP and unregulates 
HIV-1 transcription [25]. PP1 holoenzyme consists of a 
constant catalytic subunit (PP1) and a variable PP1 inter-
acting subunit such as NIPP1, PNUTS, Sds22 and others 
[26]. A Lego-like multicenter interaction of the PP1 cata-
lytic subunit and its various regulatory subunits defines 
the cellular localization, catalytic activity, and substrate-
specificity of the PP1 holoenzyme [27]. Recently, CDK9/
cyclin T1 was shown to associate with the PP1 regulatory 
subunit, PNUTS, and siRNA-mediated knockdown of 
PNUTS upregulated HIV-1 transcription [28]. Moreover, 
sequestration of PP1 through the expression of nuclear 
inhibitor of PP1 reduced HIV-1 transcription [29].
Thus, studies from our group and others showed that 
PP1 is an important regulator of HIV-1 transcription. 
We recently developed a panel of small molecular com-
pounds targeted to a non-catalytic site of PP1 and iden-
tified 1H4 compound that efficiently inhibited HIV-1 
transcription and replication [30]. We further modi-
fied 1H4 compound and obtained more potent HIV-1 
inhibitors, including 1E7-03 compound [31]. Along with 
1,2,3,4-tetrahydracridine series (1H4 derivatives) we 
evaluated other chemical scaffolds and found that some 
of these enhanced HIV-1 replication. These compounds 
contained sulfonamide linker and were structurally dis-
tinct from 1,2,3,4-tetrahydracridine series. Here, we 
characterized the effect of the HIV-1 activators using 
productively and latently infected cultured and pri-
mary cells. The most promising molecule, compound 
3, which was renamed as a small molecule activator of 
PP1 (SMAPP1), induced HIV-1 during single round rep-
lication in T cells and in latently infected Jurkat T cells, 
THP-1 cells and latently infected primary CD4+ T cells. 
Furthermore, SMAPP1 induced HIV-1 replication in pri-
mary PMBCs and latently infected ACH-2 and OM 10.1 
cells. In vitro analysis showed that SMAPP1 binds to PP1 
in  vitro using surface plasmon resonance-based Biacore 
assay and enhanced dephosphorylation of recombinant 
PP1 substrate by purified PP1. SMAPP1 specifically 
enhanced CDK9 phosphorylation at Ser90 and Thr186 
residues, but had no effect on CDK9 Ser175 residue 
phosphorylation as determined with phospho-specific 
antibodies. Proteomic analysis showed that SMAPP1 
increased expression of P-TEFb and PP1-related proteins 
including a PP1-regulatory subunit, Sds22, which was 
confirmed by immunoblotting analysis. In silico molec-
ular docking of SMAPP1 showed its preferable interac-
tion with PP1 via the binding site that is located in the 
C-terminal groove of PP1. Thus, our results indicate that 
SMAPP1 increased CDK9 phosphorylation and upregu-
lated HIV-1 transcription that led to the reactivation of 
latent HIV-1 provirus. Eventually all these events trans-
lated into enhanced HIV-1 replication and reactivation 
of latent proviruses in cellular models of HIV latency. 
Hence, our study identified a novel class of PP1-targeted 
compounds that activate latent HIV-1 provirus and that 
may be useful for future anti-HIV-1 therapeutics target-
ing HIV-1 eradication.
Results
Activation of HIV‑1 by protein phosphatase‑1 
(PP1)‑targeting compounds
We recently developed a small molecule, 1E7-03, that 
targets a non-catalytic site of PP1, interfered with the 
binding of Tat to PP1 and inhibited HIV-1 transcrip-
tion and replication [31]. The 1E7-03 compound is a 
4-benzylidene-1,2,3,4-tetrahydracridine with flexible 
carboxylic tail at position 9. We conducted a pharma-
cophore search for alternative chemical scaffolds to 
mimic aromatic moiety of the acridine scaffold and 
found that sulfonamides may serve as putative analogs. 
For instance, 2-(benzenesulfonyl)-3,4-dihydro-1H-iso-
quinoline matched aromatic option of the 1H4 (Fig-
ure  1a). Such compounds and their analogs available 
from Enamine stock were grouped in a library contain-
ing 38 new compounds which were screened by utilizing 
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a single round HIV-1 infection assay using CEM T cells 
infected with VSVG-pseudotyped HIV-1 virus express-
ing luciferase (HIV-1 Luc) as previously described [32]. 
Several compounds (Figure  1a, compounds 1, 3 and 
4) enhanced HIV-1 infection (Figure  1b, upper panel) 
without showing significant toxicity (Figure  1b, lower 
panel). The compounds were further tested in Jurkat 
and THP-1 cells latently infected with HIV-1 [33, 34]. 
In both lymphocyte and macrophage cell lines, HIV-1 
was activated by compound 3 (Figure  1c, d). We next 
tested the effect of the compounds on HIV-1 activation 
in latently infected primary CD4+ T cells (see details 
Figure 1 Activation of HIV-1 by PP1-targeting compounds. a Chemical structures of compounds 1–4 are shown. b Activation of single round HIV-1 
replication in CEM T cells. Upper panel CEM T cells were infected with VSVG-pseudotyped pNL4-3.Luc.R-E- (HIV-1 Luc) virus for 18 h and then treated 
for 24 h with the indicated concentrations of the compounds. The cells were lyzed and luciferase activity was measured. Lower panel toxicity of 
compounds was determined with trypan blue exclusion assay using an automated cell counter. c, d Activation of HIV-1 in latently infected Jurkat 
T cells and THP-1 cells. Latently infected Jurkat and THP cells were treated with the indicated concentrations of compounds for 48 h. The cells were 
lyzed and luciferase activity was measured. e Activation of HIV-1 in latently infected primary CD4+ T cells. The latently infected primary CD4+ T 
cells, harboring latent HIV provirus (pHR’P-PNL-H13LTat-δNef-GFP) with GFP reporter under LTR promoter, were treated with 5 µM of each drug in 
triplicate. The GFP expressing cells were assessed and quantified. TCR stimulation with anti-CD3/CD28 antibodies was used as positive control. The 
results depict the mean of different assays with standard deviation.
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in “Methods”). SMAPP1, as well as compounds 1 and 
4, activated HIV-1 (Figure  1e), suggesting the utility of 
these compounds during kick-and-kill cure strategy. 
Based on these observations, we chose compound 3 (and 
renamed it as small molecule activating PP1—SMAPP1 
for further analysis because it consistently activated 
HIV-1 in all tested conditions.
SMAPP1 shows no toxicity and activates HIV‑1 gene 
expression
We next analyzed the effect of SMAPP1 on single 
round HIV-1 replication and cell viability in primary 
peripheral blood mononuclear cells (PBMCs). PBMCs 
obtained from two different donors, a Caucasian and an 
African  American, were infected with HIV-1 Luc and 
treated with the compounds 1–4. At 10 μM concentra-
tions, SMAPP1 showed the best activating capability in 
a Caucasian donor-derived cells (Figure  2a, b), whereas 
expression of HIV-1 Luc in PBMCs from African Amer-
ican donor was not significantly changed. On the other 
hand, treatment with SMAPP1 led to a drastic increase 
of HIV-1 env, gag and nef RNA expression in PBMCs 
obtained from both donors as detected by quantitative 
RT-PCR (Figure  2c, d), suggesting positive effect of the 
compound on HIV-1 transcription.
At the same time, this compound showed no signifi-
cant effect on cell viability as detected by the trypan blue 
exclusion assay (Figure 2e). Taken together, these results 
indicate that SMAPP1 significantly induced HIV-1 gene 
expression and that the effect was due to the upregula-
tion of viral gene transcription.
SMAPP1 contributes to the production of HIV‑1 RNA 
in chronically infected cell lines and quiescent primary 
CD4+ T cells
To test the effect of SMAPP1 on transcription of the 
integrated HIV-1 genome, we analyzed HIV-1 RNA pro-
duction in chronically infected T lymphocytes (ACH-2) 
treated with this compound. As a positive control, we 
used a potent inhibitor of histone deacetylases (HDAC), 
suberoylanilide hydroxamic acid (SAHA) [35] which 
was recently used in preclinical trials to eliminate latent 
HIV-1 infection [36]. Treatment of ACH-2 cells pre-incu-
bated with the cocktail of antiretrovirals (lamivudine/
emtricitabine, tenofovir and indinavir each in 10 µM con-
centration) for 7 days to prevent reinfection of the cells, 
with 10 µM SMAPP1 led to two-fold induction of HIV-1 
RNA production both at 24 and 48  h post-treatment, 
with the strongest effect at 48  h (Figure  3a). Although 
the treatment with 1  µM SAHA had a more dramatic 
effect showing tenfold increased HIV-1 transcription in 
ACH-2 cells, SAHA, unlike SMAPP1, had a marked cyto-
toxic effect on the treated cells (data not shown). To avoid 
increased cell death, associated with the treatment with 
toxic doses of SAHA, we analyzed the effect of clinically 
relevant dose 0.3 µM on HIV-1 transcription within 24 h 
after treatment. The dose of SMAPP1 was also threefold 
decreased. Data in Figure  3b indicate that both com-
pounds displayed the similar 50–60% level of HIV-1 tran-
scription activation.
To test the effect of PP1 activation on HIV-1 tran-
scription in the model of latently infected primary 
cells, the PBMCs isolated from healthy donors were 
infected with HIV-1 isolate NL4-3, treated with IL-7, 
cultured for 15 days to transfer T cells to the quiescent 
stage [37], and then treated with 10 µM SMAPP1. The 
protein kinase C (PKC) agonist bryostatin-1 has been 
selected as a positive control for HIV-1 transcription 
activation based on its significant effect on HIV-1 acti-
vation in viral outgrowth assay [38]. Data in Figure 3c 
indicate that the positive effect of SMAPP1 on the 
viral transcription varied depending on the individual 
donor, but a trend of increasing HIV-1 transcription 
level could be observed. Bryostatin 1 at nanomolar 
concentrations had a significant activating effect on 
NL4-3 transcription in the infected PBMCs from all 
donors. The tested NL4-3 isolate of subtype B has been 
widely used as a model of HIV-1 infection in multi-
ple experiments. To test effect of SMAPP1 on another 
HIV-1 subtype, we infected PBMCs from the same 
donors with HIV-1 subtype C isolate 1084i from Zam-
bia, kindly provided by Dr. Charles Wood. This isolate 
was obtained from patient with slow disease progres-
sion and characterized by a prolonged clinically asymp-
tomatic period (more than 4  years) [39]. Surprisingly, 
despite the very low basic level of the virus expression 
in untreated cells, neither SMAPP1 nor bryostatin 1 
treatment had any statistically significant effects on the 
transcription (Figure 3d).
Thus, our data indicates that, SMAPP1 moderately 
activated HIV-1 NL4-3 transcription in chronically 
infected T cell lines and low-productively infected qui-
escent T cells. Despite the lower impact of SMAPP1 on 
HIV-1 transcriptional activation than the HDAC inhibi-
tor SAHA and PKC agonist bryostatin 1, the tested PP1 
targeting agent had no visible cytotoxicity at effective 
concentrations. Activation effect on the latent infec-
tion caused by HIV-1 subtype C isolate has not been 
observed.
SMAPP1 binds to PP1 and induces its activity in vitro
We analyzed the binding of SMAPP1 to recombinant PP1 
protein which was expressed in E. coli cells (see “Meth-
ods”), using surface plasmon resonance technology with a 
Biacore T-200 instrument (Figure 4a, b). PP1 was immo-
bilized on a sensor chip and different concentrations 
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of SMAPP1 were injected over the surface of the chip. 
Direct binding of the compound to PP1 was measured 
in real time and binding affinity was calculated based on 
a 1:1 binding model. SMAPP1 bound to PP1 with a Kd 
value of 183 μM, showing its ability to interact with PP1 
in vitro (Figure 4a, b).
We previously used hybrid peptides containing a retin-
oblastoma protein-derived phosphopeptide linked to an 
Figure 2 Activation of HIV-1 infection and gene expression by SMAPP1 in PBMCs. a, b Activation of one round HIV-1 infection. PBMCs obtained 
from a Caucasian donor (a) or African American donor (b) were stimulated with PHA and IL-2 and then infected with VSVG-pseudotyped pNL4-3.
Luc.R-E- (HIV-1 Luc) virus for 18 h. After that the cells were treated for 24 h with the indicated concentrations of SMAPP1. Then the cells were lyzed 
and luciferase activity was measured. c, d SMAPP1 induced HIV-1 mRNA expression in PBMCs. PBMCs obtained from a Caucasian donor (c) or Afri-
can American donor (d) were stimulated with PHA and IL-2 and then infected with HIV-1 Luc. The cells were left untreated, or treated with DMSO or 
10 μM SMAPP1 diluted in DMSO. The cells were collected after 48 h in culture, RNA was extracted, reverse transcribed and analyzed with primers for 
HIV-1 env, gag and a portion of nef remaining in the HIV-1 Luc after the insertion of luciferase. Real-time PCR was carried on Roche 4800 using 18S 
RNA as a reference. The unpaired t test was used to determine statistical significance. Asterisks indicate p ≤ 0.05. e Toxicity of compounds for PBMCs. 
PBMCs were treated with the indicated concentrations of the compounds for 24 h. Toxicity of compounds was determined with trypan blue exclu-
sion assay using an automated cell counter.
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RVxF-containing sequences derived from HIV-1 Tat as 
substrates for PP1 for the analysis of the effect of PP1-tar-
geting small molecules [30]. Here we analyzed the effect 
of SMAPP1 on dephosphorylation of the pRb-Tat peptide 
(HIPR(pS)PYKFPSSPLR KKCCFHCQVCFITK). Addi-
tion of SMAPP1 at ~3-fold molar excess (200 µM) over 
pRb-Tat (75  µM) induced pRb-Tat dephosphorylation 
and increased the rate of dephosphorylation (Figure 4c).
Thus, Biacore experiments demonstrated a direct inter-
action between SMAPP1 and PP1 and enzymatic assays 
showed that PP1 activity was increased in the presence of 
SMAPP1.
SMAPP1 induces CDK9 phosphorylation
We previously identified serine amino acid residue 90 
(Ser90) of CDK9 as CDK2 phosphorylation site and 
showed that its phosphorylation induces HIV-1 tran-
scription (reviewed in [11]). We also previously showed 
that okadaic acid, a general inhibitor of PP1 and PP2A, 
induced CDK9’s Ser 175 phosphorylation [22] and that 
expression of PP1 inhibitory peptide, cdNIPP1, induced 
CDK9’s Thr 186 phosphorylation [29]. To analyze the 
effect of SMAPP1 on CDK9 phosphorylation on Ser90, 
Ser175 and Thr186, CDK9 WT and indicated mutants 
were expressed in 293T cells, the cells were treated with 
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Figure 3 Effect of SMAPP1 on HIV-1 gene expression in chronically HIV-1 infected T cell lines and primary cells. a Chronically HIV-1 infected T cell 
line ACH-2 was pre-treated with the cocktail of antiretrovirals (lamivudine/emtricitabine, tenofovir and indinavir each in 10 µM concentrations) for 
7 days, then the cells were washed and cultured in regular medium with indicated concentrations of SMAPP1 or SAHA. The cells were harvested at 
24 and 48 h after the treatment, total RNA was isolated and subjected to quantitative RT-PCR analysis with the primers specific for HIV-1 gag. Results 
are shown as a mean of three independent experiments ±SD. Asterisk shows p value ≤0.05; double asterisk shows p value ≤0.01 between control 
cells and cells treated with SAHA. b The same cells were treated with a lower concentration of SMAPP1 or SAHA. Quantitative RT-PCR analysis of 
total RNA with oligo-dT (RT reaction) and gag-specific primers (qPCR) was performed in 24 h post-treatment. Results are shown as a mean of three 
independent measurements ±SD. Asterisk shows p value ≤0.01 between the control cells and cells treated with 3 µM SMAPP1. c, d Statistical 
analysis of the effect of SMAPP1 and bryostatin 1 on HIV-1 transcription in low-productive infected PBMCs. The PBMCs from healthy donors were 
activated with IL-2, infected with HIV-1 subtype B strains NL4-3 (c) or subtype C 1084i (d) (20 ng of p24 per 10 × 106 cells) by spinoculation and 
after 8 days cultivation in medium with IL-2 were cultured for 15 days with IL-7 to transfer T cells to quiescent phase. The cultures were treated with 
SMAPP1 or bryostatin 1 and then cultured for 48 h. Asterisk shows p value ≤0.01 between the control cells and cells treated with bryostatin 1.
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10 μM SMAPP1 or with DMSO, and CDK9 was immu-
noprecipitated and analyzed by immunoblotting with 
phospho-specific antibodies or CDK9-specific antibodies 
[25]. CDK9 Ser90 phosphorylation was increased in the 
SMAPP1-treated cells (Figure  5a, lane 2). The specific-
ity of the antibodies against CDK9 was confirmed with 
the CDK9 S90A mutant, which showed reduced phos-
phorylation of the corresponding residue (Figure  5a, 
lanes 3 and 4, Figure 5b). We next analyzed phosphoryla-
tion of CDK9 Ser 175 using phospho-specific antibodies 
obtained from Dr. Jonathan Karn and Thr186 phospho-
rylation using commercially available antibodies. While 
okadaic acid induced CDK9 Ser 175 phosphorylation 
(Figure 5c, d), there was no effect of SMAPP1 (Figure 5c, 
d). However, SMAPP1 treatment produced a small but 
statistically significant increase in CDK9 Thr186 phos-
phorylation (Figure  5c, e). Hence, SMAPP1 selectively 
induces phosphorylation at Ser90 and Thr186 residues of 
CDK9.
Effect of SMAPP1 on cellular proteome
To determine whether SMAPP1 has a global effect on 
protein expression in T cells, we conducted proteomic 






























Compound 4SMAPP1        
183 μM
Figure 4 SMAPP1 binds to PP1 and upregulates PP1 activity in vitro. a, b Direct binding of SMAPP1 to recombinant PP1 protein. The direct binding 
interaction was measured by surface plasmon resonance using a Biacore T-200 instrument. Raw data showing binding of SMAPP1 to PP1 protein 
are presented in a. The X axis represents time in seconds and the Y axis represents changes in total mass on microchip surface, which was expressed 
as resonance units. A positive deflection indicated binding of SMAPP1 in solution to PP1 protein that was immobilized on a microchip surface. Each 
line represents a different concentration of SMAPP1, all between 0 and 50 μM. Each concentration was run three times. In b, the equilibrium dis-
sociation constant (KD) was calculated based on a 1:1 binding model. The KD was calculated as 183 μM for SMAPP1 binding to PP1. Each data point 
represents the binding level shown in a from different concentrations of SMAPP1 measured just before the end of the injection (~55 s time point). 
A vertical dashed line represents the small molecule concentration that results in a binding level that is 50% of the extrapolated maximal signal. 
Experimental data points did not reach to the actual saturation level due to limitation on available SMAPP1 concentration, which resulted in the 
calculation of KD value from an extrapolated line. c SMAPP1 induces pRb-Tat dephosphorylation by PP1. Recombinant PP1α was assayed with pRb-
Tat (75 μM) in the absence or presence of 200 μM SMAPP1 as indicated. The reactions were stopped at indicated time points and the phosphate 
release was quantified by malachite green assay. Initial velocity was calculated by linear regression. Unpaired t test was used to calculate p value.
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developed protocol in which tryptic peptides from total 
cell lysates were fractionated on a cation exchange col-
umn [30]. In total, we detected over 2,000 proteins in 
the DMSO and over 3,000 proteins in SMAPP1-treated 
cells with 1,798 proteins detected in both conditions (Fig-
ure  6a). Proteins related to protein phosphatases were 
upregulated in SMAPP1-treated cells including PP1 
regulatory subunit 7 or Sds22 (Figure 6b). We used quan-
titative label-free analysis of differential peptide expres-
sion using SIVE 2.1 software for the proteins eluted in 
50 mM NaCl, which contained PP1-realted proteins and 
which showed majority of the peptides being equally 
expressed in DMSO and SMAPP1 treated cells (see 
below). Pathway analysis was performed using Ingenu-
ity software and showed several protein networks with 
upregulated protein expression including transcription 
and protein phosphatases networks (Figure  6c, d). Of 
note, in the transcription network, the level CDK9 was 
upregulated (Figure 6c). In the protein phosphatases net-
work, both PP1 and PP2A were upregulated as well as 
number of PP2A and PP1 regulatory subunits including 
PP1 regulatory subunit 7 (Sds22) and 14A (Figure  6d). 
We further analyzed the expression of PP1 regulatory 
subunit 7 (Sds22) and subunit 14A using Proteome 
Discoverer 2.1, and the results showed the presence of 
Sds22-derived peptides only in the SMAPP1 treated cells 
pSer175
CDK9
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Figure 5 Effect of SMAPP1 on CDK9 phosphorylation. a SMAPP1 induces CDK9 Ser90 phosphorylation. 293T cells were transfected with vectors 
expressing Flag-CDK9 WT (lanes 1–2) or Flag-CDK9 S90A mutant (lanes 3–4) and after 48 h in culture treated with 10 μM SMAPP1 for 24 h. CDK9 
was immunoprecipitated from cellular lysates with anti-Flag antibodies and analyzed by immunoblotting with anti-CDK9 antibodies and Ser90 
phospho-specific antibodies. b Quantification of four independent experiments similar to the one shown in a. Asterisk shows p value ≤0.05. c 
Effect of SMAPP1 on CDK9 Ser175 and Thr186 phosphorylation. 293T cells were transfected with vectors expressing Flag-CDK9 WT (lanes 2–4) or 
Flag-CDK9 S90A mutant (lanes 5–6) or Flag-CDK9 S175A (lanes 7–8) and after 48 h in culture treated where indicated with 10 μM SMAPP1 for 24 h 
or 0.1 μM okadaic acid for 2 h. Lane 1 mock transfection. CDK9 was immunoprecipitated from cellular lysates with anti-Flag antibodies and analyzed 
by immunoblotting with anti-CDK9 antibodies, Ser175 phospho-specific and Thr186 phospho-specific antibodies. d, e Quantification of two inde-
pendent experiments. Asterisk shows p value ≤0.05 and double asterisk shows p value ≤0.01 between the indicated bars.
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whereas subunit 14A was detected in both DMSO and 
SMAPP1 treated cells (Figure  7a). Expression of Sds22 
was quantified by SIEVE 2.1 that allowed extraction and 
quantification of ions from the 50 mM NaCl fraction and 
which showed the majority of the peptides being equally 
expressed in DMSO and SMAPP1 treated cells (Fig-
ure 7b). Quantification of Sds22-related peptide showed 
4.5-fold increased expression in the cells treated with 
SMAPP1 (Figure 7c). In contrast, expression of α-tubulin 
was similar in DMSO and SMAPP1-treated cells (Fig-
ure  7c). The increased Sds22 expression was confirmed 
by immunoblotting analysis with anti-Sds22 specific anti-
bodies (Figure 7d). While we do not yet know the mol-
ecule mechanism of this upregulation, our recent study 
showed that partial siRNA-mediated knockdown of PP1α 
led to the increased expression of PP1 regulatory subunit, 
SIPP1, likely as a compensatory cell response [40]. Thus, 
increased expression of Sds22 could also be a cellular 
compensatory response to PP1 deregulation or its partial 
cellular inhibition. 
In silico analysis of SMAPP1 and PP1 binding
To further analyze the effect of SMAPP1 on PP1, we con-
ducted an in silico docking analysis of the molecule on 
the surface of PP1 using ICM software and coordinates of 
the PP1 crystal structure. Molecular model of PP1α was 
built with ICM-Pro software package using PDB struc-
ture 3E7A [41]. SMAPP1 was docked to top 10 predicted 
binding sites on the surface of PP1 (Table  1). The top 
docking site with the lowest ICM score of -30.2 is shown 
in Figure  8a (overall view) and Figure  8b, which shows 







All Proteins Protein phosphatases
PP1 regulatory subunit 2
PP1 regulatory subunit 9B
PP1 regulatory subunit 7 alpha2
Protein phosphatase 1E
Dual specificity protein 
phosphatase15
Figure 6 Effect of SMAPP1 on cellular protein expression. a Venn diagram of proteins from CEM T cell proteins treated with 10 μM SMAPP1 or 
DMSO as a control. Cellular proteins were extracted, trypsinized and tryptic peptides were separated by ion exchange chromatography and then 
analyzed by high resolution mass spectrometry. Proteins were identified by Proteome Discoverer 2.1. Proteins eluted in 0, 25, 50, 100, 250 and 500 
NaCl were combined. b Venn diagram of protein phosphatase-related proteins identified in CEM T cells. c, d Peptides detected in 100 mM salt 
fraction were quantified using SIEVE 2.1 and exported to Ingenuity software for the analysis of protein networks. Transcription (c) and protein phos-
phatase (d) networks are shown. Up-regulated genes are colored in red and down-regulated genes are colored in green.
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Taken together, our results indicated that we have 
identified a small molecule compound, SMAPP1, which 
can induce HIV-1 transcription and reactivate latent 
HIV-1 provirus. This compound increases CDK9 phos-
phorylation on several key residues and activates PP1 
in vitro and also induces Sds22 expression in the treated 
T cells.
Discussion
In the present study, we extended our previous findings 
of the small molecule mimetics of the “RVxF”-docking 
peptide by identifying compounds that activate HIV-1. 
We previously identified HIV-1 inhibitory 1H4 com-
pound [30] and, more recently, 1E7-03 compound [31]. 
Both molecules disrupt the interaction of HIV-1 Tat’s 
RVxF sequence with PP1 in vitro and inhibit HIV-1 tran-
scription as well as replication in cultured cells [31]. In 
the current study, we have developed a novel library of 
sulfonamide-containing compounds and, out of this 
library, identified a novel compound SMAPP1 which is 
able to induce HIV-1 transcription and replication with 
no observed toxicity.






































Figure 7 Induction of Sds22 expression by SMAPP1. a Proteome Discoverer analysis of Sds22 expression. CEM T cells were treated with 10 μM 
SMAPP1 or DMSO as control and proteins were analyzed by mass spectrometry. Proteins containing “protein phosphatase” query identified in 
Proteome Discoverer 2.1 are shown. Sds22 is indicated in red. b Quantitative analysis by SIEVE 2.1. The volcano plot shows ratios of peptides present 
in 100 mM salt fraction in SMAPP1 versus DMSO treated samples with corresponding p values. c Quantitative analysis of Sds22 expression using 
SIEVE 2.1. Ion elution profiles are shown in blue for control samples and in red for the CEM T cells treated with SMAPP1. Triangles indicate the time 
points at which MS/MS was conducted. The upper panel shows the elution of the Sds22-derived ion. The lower panel shows the elution of the 
α-tubulin-derived ion. Results from two independent experiments are shown. Integration of the peaks was performed by SIEVE 2.1 and the ratios of 
the ion peaks in SMAPP1 versus control cells are shown. d Validation of Sds22 expression by Western blotting. CEM T cells were treated with 5 µM of 
SMAPP1 overnight. Cell lysates were resolved on 10% SDS-PAGE and immunoblotted with antibodies against Sds22 or α-tubulin as loading control. 
Four separate experiments were conducted and quantified as shown in the lower panel. Asterisks indicate p < 0.05.
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We used several cell-based models of HIV-1 latency 
to test the effect of PP1-targeting small molecule com-
pounds on the activation of viral expression. These 
include one round HIV-1 infection, latently infected Jur-
kat (lymphoblastoid T cells), THP (monocytes) cell lines, 
chronically infected CEM T cells (ACH-2) and primary 
CD4+ T cells within the pool of infected PBMCs treated 
with IL-7 to transfer them to quiescent phase. While 
SMAPP1 induced HIV-1 in chronically and latently 
infected T cell line two to threefold, in PBMCs we could 
not detect significant effect on total HIV-1 transcription, 
whereas a trend to transcription reactivation, especially 
in the case of HIV-1 subtype B infection, was observed. 
On the other hand, analysis of HIV-1 gene expression in 
acutely-infected PBMCs from various donors, treated 
with SMAPP1, showed increased transcription of HIV-1 
mRNA; the level of both unspliced and single-spliced 
mRNA species was detected. High variability of SMAPP1 
effect on HIV-1 transcription in the cells from differ-
ent donors, as well as lack of visible effect on the tran-
scription of HIV-1 subtype C virus genome within the 
low-productive infection in primary cells suggests that 
impact of this compound on HIV-1 infection depends 
on the nature of infected cells and probably the virus 
subtype.
Our previous studies showed that HIV-1 Tat interacts 
with PP1 and translocates it to the nucleus [42]. PP1-
targeting HIV-1 inhibitory compound 1E7-03 prevents 
interaction of Tat with PP1 and nuclear targeting of PP1 
[31]. CDK9 was shown to be phosphorylated on T-loop 
residues, Ser175 and Thr186, and also on Ser90 located 
within a loop which is adjacent to the T-loop (reviewed 
in [11]). The CDK9 Thr186 phosphorylation is required 
for the enzymatic activity of CDK9 and also facilitates 
the association of CDK9/cyclin T1 with 7SK RNA snRNP 
[20, 21]. CDK9 Thr186 is phosphorylated by CDK7/cyc-
lin H [43]. CDK7/cyclin H has now emerged as a uni-
versal CDK-activating kinase that phosphorylates and 
regulates cell-cycle-related CDKs, such as CDK1, 2 and 
4, and also CDKs involved in transcriptional regulation 
such as CDK8, 9, 12 and 13 (see for details [44]). We 
showed that inhibition of PP1 increased phosphorylation 
Table 1 Prediction for SMAPP1 binding to PP1α using ICM docking algorithm
# Docking site (PP1 residue number) Cavity volume, Å3 Best ICM score
1 20–22, 24–25, 67–71, 73–74, 77, 96–99, 270–274, 299 334.5 −30.2
2 208–211, 218–221, 226, 246, 249, 251, 256–258, 263, 265 195.5 −20.1
3 64, 66, 92, 96, 124–125, 130, 134, 206, 221, 248–250, 267, 272 198.4 −5.6
4 49–50, 53–56, 59, 86, 116:117, 119 116.6 −18.2
5 47, 49–52, 187:191 121.6 −22.9
6 176–178, 180–181, 216, 231, 234–235, 238 129.9 −16.0
7 56–60, 84–86, 284–286 57.4 −21.3
8 197–198, 218–219, 222–225 78.3 −18.2
9 211, 229, 257–261 56.3 −22.6
10 124, 127, 129–130, 195–197, 202, 206, 223 72.1 −18.6
Figure 8 SMAPP1 binds to the C-terminal groove of PP1. a Model of SMAPP1 binding to PP1. A model was constructed by docking analysis with 
ICM software. b Predicted binding position of SMAPP1 on the PP1α surface. Protein surface is shown in gray color, cavity #1 (see Table 1) is shown in 
transparent green color. Several protein residues are labeled for clarity.
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of CDK9 Ser175 residue, decreased CDK9 activity and 
reduced RNA polymerase II phosphorylation in  vivo 
[22]. Recently, reduced CDK9 Ser175 phosphorylation 
was shown to enhance HIV-1 transcription by preventing 
CDK9/cyclin T1 interaction with Brd4 making CDK9/
cyclin T1 available for recruitment by HIV-1 Tat pro-
tein [24]. However, in activated T cells CDK9 Ser175 was 
phosphorylated, and this phosphorylation increased the 
affinity of CDK9/cyclin T1 to Tat [24]. We also recently 
showed that CDK9 Ser90 is phosphorylated by CDK2 
and that this phosphorylation induces HIV-1 transcrip-
tion [25]. Analysis of CDK9 phosphorylation in the cells 
treated with SMAPP1 conducted here showed increased 
Ser90 phosphorylation suggesting that PP1 might either 
directly control CDK9 Ser90 phosphorylation or have an 
indirect effect on CDK2 activity. In vitro, we observed 
dephosphorylation of CDK9 by PP1 when CDK9 was 
phosphorylated by CDK2 (Ammosova and Nekhai, 
unpublished) suggesting that PP1 may also dephospho-
rylate CDK9 Ser90.
We analyzed the effect of SMAPP1 on PP1 in  vitro, 
using a Biacore assay with Chip-immobilized bacterially 
expressed PP1. While we observed relatively weak bind-
ing with Kd = 183 μM, the presence of SMAPP1 induced 
dephosphorylation of a peptide substrate containing an 
RVxF motif suggested that it may interfere with the bind-
ing of RVxF motif or some other sites where the hybrid 
substrate interacts with PP1. The latter is further sup-
ported by the in silico docking analysis, which showed 
preferred interaction of SMAPP1 with the C-terminal 
groove of PP1, which may also be involved in the interac-
tion of the peptide substrate with PP1. Analysis of pro-
teins expressed in T cell treated with SMAPP1 showed 
upregulation of the PP1-regulatory subunit, Sds22. 
Expression of Sds22 was also verified by immunoblotting 
analysis. Sds22 is evolutionarily conserved ancient inter-
actor of PP1 that along with Inhibitor 3 forms a com-
plex with PP1 and helps to translocate it to the nucleus 
[45]. Sds22 also converts PP1 to inactive form [45]. Thus, 
over expression of Sds22 may change the cellular distri-
bution of PP1 and potentially deregulate cellular PP1 or 
reduce PP1 availability for Tat recruitment and CDK9 
dephosphorylation. While the crystal structure of PP1 in 
complex with Sds22 is yet to be determined, biochemi-
cal studies showed that the N-terminal part of the PP1 
C-terminal groove might interact with Sds22 [46]. Thus 
SMAPP1 can potentially interfere with the binding of 
Sds22 to PP1 leading to the upregulation of Sds22 expres-
sion as a cellular compensatory response.
Our study shows that HIV-1 can be induced by a 
small molecular compound that interferes with PP1 [1]. 
These results are significant in light of the current ther-
apy named the kick-and-kill approach where HDAC 
inhibitors are used to activate the virus followed by com-
bination antiretroviral therapy (cART). Current ideas to 
use HDAC inhibitors for virus reactivation are promis-
ing since this method provides four to fivefold increase in 
viral replication [47]. The cART is efficient in eradicating 
the circulating virus in plasma by inhibition of produc-
tive infection. However, the current drug compositions 
are not able to completely eliminate the virus [48], since 
HIV-1 is capable of maintaining latent infection in sta-
ble reservoirs such as resting CD4+ T cells, naive T cells 
and CD34+ multipotent hematopoietic stem cells [49, 
50]. Furthermore, interruption of the therapy leads to the 
rapid increase of viral population [51, 52], whereas a long 
combinational cART treatment has negative side effects, 
including fatigue, diarrhea [53], neurocognitive abnor-
malities, cardiovascular diseases [54–56]. Here, we show 
that SMAPP1 is the first example of small molecule tar-
geting PP1 that induces HIV-1 transcription and poten-
tially could be used as the latency reversing agents in 
patients on cART treatment. Combination of the latency 
reversing drugs such as PKC agonist bryostatin showed 
improved HIV-1 activation with the reduction of toxicity 
[57]. We are currently testing a synergy of SMAPP1 with 
SAHA and other HDAC inhibitors. Taken together, our 
study points to PP1 as a new drug target for novel antiret-
roviral therapeutics. These therapeutics can be aimed at 
reversing HIV-1 latency as we show here with SMAPP1 
which will have to be used with cART to prevent virus 
rebound. Alternatively, PP1 can be targeted to cure HIV-1 
with PP1-targeting HIV-1 inhibitors such as 1E7-03 [58] 
which can be used alone or in combination with cART.
Methods
Cells were obtained from ATCC (Manassas, VA, USA). 
pNL4-3.Luc.R−E− (Gervaix et  al. 1997), as well as 
latently-infected CEM subclone ACH-2 [59] and chron-
ically-infected subclone of promyelocytic HL-60 cell line 
OM10.1 [60] were obtained from the NIH AIDS Research 
and Reference Reagent Program. PBMCs were purchased 
from Astarte Biologics (Redmond, WA, USA). Anti-Flag 
antibodies and anti-tubulin antibodies were from Sigma 
(Atlanta, GA, USA). Protein G agarose was from Upstate 
(Lake Placid, NY, USA). Antibodies against PP1α were 
from EMD Chemicals (Gibbstown, NJ, USA). Anti-GFP 
and anti-CDK9 antibodies were from Santa Cruz Bio-
technology (Dallas, TX, USA). CDK9 Thr186 phospho 
specific antibodies were from Cell Signaling Technology 
(Beverly, MA, USA). CDK9 Ser175 phospho specific anti-
bodies were a gift from Dr. Jonathan Karn (Case Western 
Reserve University). CDK9 Ser90 phospho specific anti-
bodies were prepared by Dr. Monique Beullens (Catholic 
University of Leuven, Belgium) as previously described 
[25].
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Design of the 1E7‑03 derivatives library
To generate novel compounds with alternative chemical 
scaffolds, we conducted a pharmacophore search from 
Enamine stock collection followed by visual selection. A 
phase program from the Schrodinger suite was used for 
screening. Pharmacophore model was constructed using 
atoms of the aromatic groups and ester oxygen at posi-
tion 9 of the acridine core. Putative ligands were consid-
ered for those which matched at least 3 pharmacophore 
points (out of 5) with the acridine pharmacophore model. 
The preference was given to sulfonamides enriched with 
aromatic groups. An acridine series with the amide group 
instead of ester in position 9 of the acridine were pre-
pared at Enamine facilities. In total, 38 compounds were 
included into this study.
Single round HIV‑1 replication assay
CEM T cells or PBMCs were infected with VSVG-pseu-
dotyped pNL4-3.Luc.R-E-virus (HIV-1 Luc) prepared as 
previously described [32]. PBMCs were stimulated by 
treating with 2.5 μg/mL phytohemaggultinin (PHA) for 
24 h and then activated for another 24 h with 10 units/
mL IL-2 before the infection with HIV-1 Luc. PBMCs 
were infected with HIV-1 Luc, cultured at 0.5 × 106 cells/
mL in 6-well plates at 37°C and 5% CO2 for 24 h and then 
treated with indicated concentrations of compounds. The 
cells were collected after 48  h in culture, washed with 
PBS and resuspended in 100 μL of PBS. Then, 100 μL of 
reconstituted luciferase buffer (Luclite Kit, Perkin Elmer) 
was added to each well and after 10 min incubation. The 
lysates were transferred into white plates (Perkin Elmer) 
and luminescence measured using Labsystems Luminos-
can RT equipment (Perkin Elmer).
Cell viability assays
CEM T cells or PBMCs were cultured as described above 
in 96-well plates at 37°C. Cell viability was determined 
by trypan blue assay using TC-10 automated cell counter 
(Bio-Rad).
HIV‑1 activation in ACH‑2 cells
The cells were plated in 6-well plates at a concentration of 
106 cells/mL in RPMI. The cells were then incubated with 
varying doses of compounds for 36–48 h. Cells were har-
vested from the wells by scraping and washed three times 
with PBS. Luciferase levels in the cells were assessed 
using a commercial kit (Promega; Madison, WI, USA). 
Briefly, the cells were lysed for 30 min at room tempera-
ture with passive lysis buffer and centrifuged at 10,000×g 
for 2 min. Then 10 µl of samples were added to individual 
wells, followed by 70 µl luciferase substrate/assay buffer. 
Samples were tested in triplicates. Luminescence was 
measured in a Veritas Microplate Luminometer (Turner 
Biosystems).
HIV‑1 activation in chronically infected cell lines
Chronically HIV-1 infected cell lines ACH-2 cells were 
maintained at 37°C and 5% CO2 in 25 and 75 cm2 tissue 
culture flasks with RPMI-1640 culture medium supple-
mented with 10% Fetal Bovine Serum, penicillin/strep-
tomycin (100 μg/mL), and l-Glutamine (lymphoid and 
myeloid cells). Before experiments, the cells were incu-
bated for 7  days with the cocktail of four antiretroviral 
drugs (Emtricitabine, Tenofovir, Indinavir, and Lamivu-
dine), each in concentration 10 µM. Then the cells were 
washed with PBS and cultured in regular media, with 
various concentrations of solutions of SMAPP1 or SAHA 
diluted in DMSO. The control cells were treated with 
equivalent volumes of DMSO. The cells were harvested 
at 24 and 48 h post-treatment, the total RNA was isolated 
and used for quantitative RT-PCR analysis.
Establishment of latently HIV‑1 infected primary CD4+ T 
cells
Briefly, the primary CD4+ T-cells were isolated from 
either PBMCs (peripheral blood mononuclear cells), 
activated using a-CD3/CD28 antibodies and infected 
with HIV-dNef-IRES-GFP virus. The pure population 
of HIV infected cells (GFP expressing) was purified by 
FACS sorting and further expanded with a-CD3/CD28 
antibodies. Once cell population reached between 50 
to 100 × 106, the cells were placed on feeder cells in the 
presence of IL-2 to allow proviral latency establishment. 
Usually, after 6 weeks most of the cells enter into a qui-
escent state, characterized by loss of GFP expression, 
the cessation of DNA synthesis and a huge reduction in 
cell size [61]. Cell characterizations demonstrate that 
majority have a central memory phenotype. Very few of 
the silenced cells have lost the provirus, since more than 
95% could be efficiently reactivated via T cell receptor 
stimulation.
Model of latent infection with HIV‑1 in PBMCs
Total PBMCs from healthy seronegative donors were 
activated with 50 U/mL IL-2 and cultured for 4  days. 
Then the cells were infected with a replication competent 
HIV-1 strains NL4-3 (subtype B) or 1084i (subtype C) by 
spinoculation at 1,200×g for 2  h at room temperature. 
Infected cultures were expanded to 8  days in medium 
containing 50  U/mL IL-2. When the infected culture 
contained 10–15% infected cells as determined by qPCR, 
the cultures were placed in a quiescent phase for 15 days 
by cultivation in the medium containing 1  ng/mL IL-7. 
At the end of the 15 days resting phase, the cultures were 
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treated with SMAPP1 compound or control drugs and 
then cultured for 24 or 48 h.
RNA isolation and quantitative RT‑PCR
For quantitative analysis of HIV-1 RNA, total RNA was 
purified from the lysates of chronically HIV-1 infected 
cell lines ACH-2 and OM-10.1. RNA was isolated using 
Trizol Reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s protocol. A total of 0.5 μg of RNA 
from the RNA fraction was treated with 0.25  mg/mL 
DNase I RNase-free (Roche, Mannheim, Germany) for 
60 min in the presence of 5 mM MgCl2, followed by heat 
inactivation at 65°C for 15  min. A 200–250  ng aliquot 
of total RNA was used to generate cDNA with the GoS-
cript Reverse Transcription System (Promega, Madison, 
WI, USA) using oligo-dT reverse primers. Subsequent 
quantitative real-time PCR analysis was performed with 
2 µl of undiluted and 10−1, and 10−2 diluted aliquots of 
RT reaction mixes. The iQ SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA) was used with the primers 
specific for HIV-1 gag gene: Gag1483-F (5′-AAGGGG 
AAGTGACATAGCAG-3′) and Gag1625-R (5′-GCTGG 
TAGGGCTATACATTCTTAC-3′) amplifying 143 
nucleotide fragment of HIV-1 gag gene. Serial dilu-
tions of DNA from 8E5 cells (a CEM T cell line contain-
ing a single copy of HIV-1 LAV provirus per cell) were 
used as the quantitative standards. To normalize HIV-1 
RNA quantifications in the human cells to the target 
cell DNA, the β-globin gene was quantified by real-time 
PCR using a set of β-globin-specific primers: BGF1: 
5′-CAACCTCAAACAGACACCATGG-3′), BGR1: 5′-TC 
CACGTTCACCTTGCCC-3′ and probe BGX1: 5′-FAM-C 
TC C TGAG GAGA AGTC TG C C GT TAC TG C C-T 
AMRA-3′. Real-time PCR reactions were carried out 
at least in triplicate using the PTC-200 Peltier Thermal 
Cycler with Chromo4 Continuous Fluorescence Detec-
tor (both from MJ Research) and Opticon Monitor 2.03 
software.
Transfections
293T cells were seeded in 6 well plates to achieve 50% 
confluence on the day of transfection. The cells were 
transfected with the indicated plasmids using Lipo-
fectamine Plus reagent (Life Technologies) following the 
manufacturer’s protocol. The efficiency of transfection 
was verified using a plasmid encoding green fluorescent 
protein. The cells were cultured for 48  h post-transfec-
tion and then analyzed for phosphorylation of CDK9.
Immunoprecipitations
293T cells were lysed in whole cell lysis buffer (50  mM 
Tris–HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) sup-
plemented with protease cocktail. CDK9 was precipitated 
with anti-Flag antibodies as we previously described [25]. 
Briefly, 400 μg of lysate and 800  ng of antibodies com-
bined with 50 μL of 50% slurry of protein A/G agarose 
were incubated for 2 h at 4°C in a TNN Buffer (50 mM 
Tris–HCl, pH 7.5, 150  mM NaCl and 1% NP-40). The 
agarose beads were precipitated, washed with TNN 
buffer, resolved in 10% Tris–Glycine SDS-PAGE, trans-
ferred to polyvinylidene fluoride (PVDF) membranes and 
immunoblotted with appropriate antibodies.
Western blot analysis
Whole cell lysates of CEM cells treated with SMAPP1 
were prepared by the addition of 1X SDS and the samples 
were heated for 5  min at 95°C. The samples were then 
resolved in 10% SDS-PAGE and transferred to a PVDF 
membrane. The membrane was blocked with 5% milk in 
PBS supplemented with 0.1% Tween-20 and probed with 
Sds22 and α-tubulin antibodies. Images were developed 
on ChemiDoc™ XRS + System (Bio-Rad).
Sample preparation for mass spectrometry analysis
CEM T cells were collected and lysed with whole cell lysis 
buffer (50 mM Tris HCl, 500 mM NaCl, 1% NP40, 0.1% 
SDS) that was supplemented with protease inhibitors. 
The insoluble nuclear material was removed by centrifu-
gation for 20 min at 21,000×g. The supernatant was col-
lected and protein concentration was measured using the 
BCA protein assay. Proteins were precipitated with cold 
acetone (4× the volume of the cell lysate volume) and 
incubated at −20°C for 30  min. The samples were then 
centrifuged at 13,000×g for 10 min and the supernatant 
was discarded. The pellets were dried for 10 min at room 
temperature and then resuspended in 100 μL of 100 mM 
ammonium bicarbonate buffer containing 10  mM 
DTT. The samples were heated at 95°C for 5  min to be 
reduced. The samples were then alkylated with 15  mM 
iodoacetamide in the dark for 20 min at room tempera-
ture. Trypsin gold was then added and the samples were 
incubated overnight at 37°C. A 100 mg C18 solid phase 
cartridge (Discovery, Supleco) was activated with 1  mL 
of methanol. The column was then equilibrated with 
0.046% of trifluoroacetic acid. Trypsin hydrolyzates were 
passed through the column, which was then washed with 
0.046% trifluoroacetic acid and the samples were eluted 
with 80% acetonitrile containing 0.046% of trifluoro-
acetic acid. A column was prepared by cutting a small 
piece of glass fiber (Applied Biosystems) with a 1  mL 
micropipette tip that has been clipped. The glass fiber 
was fed into a 200 μL pipette tip by a 1 mL pipette with a 
clipped tip and 20% SCX resin (POROS 50 HS, Perspec-
tive Biosystems) was added to the pipette tip. The col-
umn was equilibrated with 100 μL of 0.5% formic acid in 
0.25% acetonitrile (equilibration buffer). Sodium chloride 
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(NaCl) solutions (concentrations 25–500 mM) were pre-
pared in equilibration buffer. The samples were loaded in 
the column and washed twice with 100 μL equilibration 
buffer. The samples were then collected with the varying 
concentrations of NaCl solution and then dried again in a 
Speed-Vac centrifuge (Savant).
Mass spectrometry and data analysis
The mass spectra of the peptides were detected with a 
data-dependent 4-event scan method (a survey FT-MS 
parent scans followed by sequential data-dependent 
FT-MS/MS scans on the three most abundant pep-
tide ions from the parent scan). Protein identifications 
were carried out with Proteome Discoverer 1.2 software 
using the SEQUEST search engine for protein database 
searching and using the International Protein Index (IPI) 
Human Protein Database (version 1.79). A sequential 
database search was performed using human FASTA 
database. Only peptides having cross-correlation (XCorr) 
cutoffs of 2.6 for [M + 2H]2+, 3.0 for [M + 3H]3+ and 
higher charge state were considered. These SEQUEST 
criteria thresholds typically result in a 1–2% of False 
Discovery Rate. FDR was determined by searching on a 
decoy database. We used SIEVE 2.1 software (Thermo) 
for label-free quantitative analysis of the high resolution 
MS spectra produced by Orbitrap MS scans. We also 
explored protein networks in SMAPP1-treated cells by 
uploading the results of SIEVE 2.1 analysis into Ingenuity 
(Qiagen) and performing pathway analysis.
Expression of recombinant PP1
BL21 (DE3) E. coli cells (Invitrogen) were co-transformed 
with al vector RP1B, which expresses human PP1α (resi-
dues 7-300), and pGR07, which expresses GroEL/GroED 
chaperones (both gifts from Dr. Mathieu Bollen and 
Monique Beullens, KULeuven, Belgium). The cells were 
grown in media supplemented with 1  mM MnCl2 at 
30°C to an A600 ~ 0.5. Then arabinose (2 g/L) was added 
to induce expression of the GroEL/GroES chaperones. 
When A600 ~ 1 was reached, the cells were transferred to 
10°C and PP1 expression was induced with 0.1 mM IPTG 
for 20  h. Harvested cells were lysed using sonication 
in a solution containing in 50  mM Tris–HCl (pH 8.0), 
5 mM imidazole, 700 mM NaCl, 1 mM MnCl2, 0.1% Tri-
ton X-100 (v/v) and protease inhibitors. His-tagged PP1 
was purified using a Ni–NTA IMAC column (Qiagen). 
PP1 was then dialyzed and stored at −70°C in 50  mM 
Tris–HCl (pH 8.0), 5 mM imidazole, 700 mM NaCl, and 
1 mM MnCl2. PP1 activity was then assayed as previously 
described [30].
Surface plasmon resonance (SPR)
All SPR measurements were conducted on a Biacore 
T200 instrument (GE Healthcare, Piscataway, NJ, USA) 
at 25°C. Recombinant His-tagged PP1 was immobilized 
on a Ni–NTA sensor chip (GE Healthcare). The two 
flow cells of the sensor chip were primed with running 
buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% v/v 
Surfactant P20, 1% DMSO and 2 mM MnCl2) and loaded 
with 0.5 mM NiCl2 at a flow rate of 10 μL/min for 180 s. 
After NiCl2 injection, both flow cells were washed twice 
with the running buffer at flow rate of 100 μL/min for 
40  s. PP1 was diluted with the running buffer to a con-
centration of 200 nM and was then passed over the sec-
ond flow cell of the sensor chip at a flow rate of 5 μL/min. 
The final amount of PP1 immobilized on the surface was 
3,500 RU. The first flow cell was only loaded with Ni2+ 
and was used as a reference for non-specific background 
binding during the experiment. For binding and kinet-
ics experiments, all compounds were diluted in the run-
ning buffer, at 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 μM 
and were passed over the two flow cells at a flow rate of 
100 μL/min for 60 s. The number of response units was 
recorded after the subtraction of the reference flow cell’s 
value (Fc2-1). Three repetitions were performed for each 
injection. Data were analyzed using the BiaEvaluation 
software of Biacore with a 1:1 binding model.
Molecular modeling
All molecular modeling was performed using ICM-Pro 
software package v. 3.8-1 (Molsoft LLC, USA). 3D atomic 
structures of PP1α were taken from the PDB database 
(PDB IDs: 1FJM, 3E7A, 3E7B, 3EGG, 3EGH, 3HVQ, 
3  N5U). Preliminary analysis showed high similarity of 
these structures (mean pairwise RMSD of Cα atoms of 
the main protein chain was below 0.5 Å). Structure 3E7A 
[41] with the best resolution of 1.6 Å was selected to 
build the molecular model of PP1α. The 2,400 hydro-
gen atoms were added and conformations of the side 
chains were locally optimized. The amino acid residues 
were renumbered in according to the sequence PP1A_
HUMAN (UniProt ID: P62136). Cavities on the surface 
of the molecular model of PP1α were found using an icm-
PocketFinder algorithm [62]. The cavities grid map was 
contoured at 4σ level and split into individual cavities. 
Top 10 biggest cavities were used to determine the dock-
ing sites (amino acid residues in 3 Å vicinity). Standard 
ICM docking was performed for each docking site, as 
described in [63]. Thoroughness parameter was set to 10. 
ICM score was calculated for the top 10 positions of the 
ligand.
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Statistical analysis
Results are expressed as mean ±  SD or ±SEM. Differ-
ences between any two groups were compared with the 
unpaired two-tailed Student’s t test on GraphPad Prizm 
4.01 software (GraphPad Software, La Jolla, CA, USA).
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